Uncategorized
Glaukos completes enrollment in iStent Supra trial
Enrollment in the investigational device exemption trial for the iStent Supra for treatment of patients with open-angle glaucoma and cataracts has been completed, Glaukos announced in a press release. The prospective, randomized clinical trial includes 505 subjects across 36 sites. Patients will receive either the iStent Supra with cataract surgery or cataract surgery alone. The study aims for at least a 20% reduction in IOP from baseline in 24 months.